Korea's leading vaccine makers face tougher competition

Published: 2003-07-29 06:59:00

Updated: 2003-07-29 06:59:00

Domestic major hepatitis B vaccine makers, such as Korea Green Cross and LG Life Sciences, are desperately bracing for their R&D new product strategies in the wake of falling profit margins incurred more intense competition in the global vaccine tender market allowing new successful bidders such ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK